View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 27, 2020

ANA Therapeutics begins trial of oral niclosamide for Covid-19 treatment

Biotech firm ANA Therapeutics has begun Phase II/III trial to analyse the safety and efficacy of its oral niclosamide (ANA001) formulation for treating patients with moderate Covid-19. 

Biotech firm ANA Therapeutics has begun Phase II / III trial to analyse the safety and efficacy of its oral niclosamide (ANA001) formulation for treating patients with moderate Covid-19.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

The trial is a first-of-its-kind in the US, analysing niclosamide, traditionally used for treating tapeworm infections, against Covid-19.

Pre-clinical data from an independent academic group showed that niclosamide prevented viral replication in vitro and was more potent than remdesivir. It works as an SKP2-inhibitor, reducing viral replication.

The drug also demonstrated anti-inflammatory activity through NF-κB and STAT3, transcription factors that stimulate the expression of molecules that propel inflammation.

ANA Therapeutics chief scientific officer Nadja Mannowetz said: “Niclosamide has demonstrated antiviral as well as immune-modulating activities in preclinical studies.

“This trial provides the first opportunity to evaluate its safety and potential to improve clinical outcomes and reduce hospital stay by reducing viral load, inflammation linked to cytokine dysregulation, acute respiratory distress syndrome, and disease-related blood coagulation.”

The multi-centre, randomised, placebo-controlled trial will take place in two parts across 20 clinical sites in the US.

Hospitalised patients with moderate Covid-19 who do not require ventilators will receive a seven-day course of niclosamide capsules.

The primary objective of the trial’s first part is to analyse safety and tolerability while secondary objectives include measurement of efficacy and pharmacokinetics.

Primary objectives of the second part are to analyse niclosamide’s efficacy, safety and tolerability. While secondary goals will analyse clinical improvement and the need and duration for rescue therapy.

The new formulation of niclosamide enters the bloodstream to target the virus.

ANA Therapeutics co-founder and COO Andrew Bartynski said: “The original niclosamide product was designed to work in the gut, where tapeworms reside, and not enter the bloodstream.

“We have developed a proprietary formulation intended to enable the drug to readily enter the bloodstream at levels sufficient to stop the virus from replicating.”

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology